CLINUVEL PHARMACEUTICALS LIMITED - Announcements

0.09%

$10.65

Market Cap $536.8M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

CUV	Chair's Letter to Shareholders		05/09/25	145.84KB	Share
CUV	Date of Annual General Meeting		03/09/25	66KB	Share
CUV	CLINUVEL Annual Results - Investor Webinar		29/08/25	64.06KB	Share
CUV	Investor Presentation	PRICE SENSITIVE	28/08/25	1.53MB	Share
CUV	Corporate Governance Statement		28/08/25	268.03KB	Share
CUV	Appendix 4G		28/08/25	295.41KB	Share
CUV	Dividend/Distribution - CUV		28/08/25	13.51KB	Share
CUV	CLINUVEL delivers ninth consecutive revenues growth & profit	PRICE SENSITIVE	28/08/25	139.49KB	Share
CUV	Appendix 4E and Annual Report to Shareholders 2025	PRICE SENSITIVE	28/08/25	18.09MB	Share
CUV	CLINUVEL preparing upgrade of ADR program, NASDAQ uplist	PRICE SENSITIVE	22/08/25	100.09KB	Share
CUV	CLINUVEL Annual Results - Investor Webinar		21/08/25	71.54KB	Share
CUV	Bioshares Biotech Summit presentation		07/08/25	1.85MB	Share
CUV	Presentation to BTIG Biotech Conference		30/07/25	1.4MB	Share
CUV	Notification of cessation of securities - CUV		02/07/25	12.69KB	Share
CUV	German Non-deal Roadshow Presentation		24/06/25	1.74MB	Share
CUV	Ceasing to be a substantial holder		19/06/25	960.45KB	Share
CUV	Study confirms NB-UVB needed to activate repigmentation	PRICE SENSITIVE	18/06/25	94.13KB	Share
CUV	Becoming a substantial holder		18/06/25	873KB	Share
CUV	CLINUVEL management update	PRICE SENSITIVE	13/06/25	66.76KB	Share
CUV	SCENESSE successfully administered to paediatric EPP patient		13/06/25	67.24KB	Share
CUV	SCENESSE in Vitiligo - A Global Update		04/06/25	18.55MB	Share
CUV	SCENESSE EPP data featured at EADV Symposium		22/05/25	77.38KB	Share
CUV	Ceasing to be a substantial holder		09/05/25	1.15MB	Share
CUV	CUV recruits 200 patients in Phase III vitiligo trial CUV105	PRICE SENSITIVE	07/05/25	275.36KB	Share
CUV	Notification regarding unquoted securities - CUV		23/04/25	16.96KB	Share
CUV	Notification of cessation of securities - CUV		09/04/25	12.69KB	Share
CUV	Section 708A Cleansing Statement		07/04/25	92.92KB	Share
CUV	Application for quotation of securities - CUV		07/04/25	16.47KB	Share
CUV	Application for quotation of securities - CUV		07/04/25	15.56KB	Share
CUV	Change in substantial holding		01/04/25	1.46MB	Share
CUV	Notification of buy-back - CUV		27/03/25	13.13KB	Share
CUV	CLINUVEL renews share buy-back program	PRICE SENSITIVE	27/03/25	71.89KB	Share
CUV	Update - Notification of buy-back - CUV		27/03/25	15.25KB	Share
CUV	Positive preliminary results for PRENUMBRA Instant in stroke	PRICE SENSITIVE	26/03/25	93.68KB	Share
CUV	2025 American Academy of Dermatology Annual Meeting		24/03/25	5.66MB	Share
CUV	CLINUVEL management update	PRICE SENSITIVE	18/03/25	64.26KB	Share
CUV	CLINUVEL Unveils Vitiligo Program for AAD 2025		04/03/25	108.92KB	Share
CUV	CLINUVEL Investor Webinar		28/02/25	60.69KB	Share
CUV	Chair Letter to Shareholders		28/02/25	84.04KB	Share
CUV	Half Year Results Presentation	PRICE SENSITIVE	27/02/25	848.02KB	Share
CUV	Half Year Results Announcement	PRICE SENSITIVE	27/02/25	130.47KB	Share
CUV	Appendix 4D and Half Year Report	PRICE SENSITIVE	27/02/25	885.32KB	Share
CUV	CLINUVEL Investor Webinar		20/02/25	109.21KB	Share
CUV	Change in substantial holding		17/02/25	1.31MB	Share
CUV	Preliminary results from SCENESSE adolescent EPP study	PRICE SENSITIVE	10/02/25	117.52KB	Share
CUV	Vitiligo - CUV105 Study Update	PRICE SENSITIVE	20/01/25	2.65MB	Share
CUV	SCENESSE Argentinian distribution agreement		17/01/25	68.34KB	Share
CUV	Managing Director Letter to Shareholders		23/12/24	96.75KB	Share
CUV	Health Canada validates SCENESSE New Drug Submission	PRICE SENSITIVE	23/12/24	68.68KB	Share
CUV	Revised Securities Trading Policy		18/12/24	211.55KB	Share
CUV	Becoming a substantial holder		06/12/24	1.24MB	Share
CUV	Chair's letter to Shareholders	PRICE SENSITIVE	05/12/24	83.86KB	Share
CUV	Notification of cessation of securities - CUV		04/12/24	12.69KB	Share
CUV	SCENESSE dosage expansion under review by EMA	PRICE SENSITIVE	20/11/24	87.02KB	Share
CUV	CLINUVEL Bell Potter Healthcare Conference Presentation		18/11/24	430.71KB	Share
CUV	CLINUVEL prioritises three strategic programs	PRICE SENSITIVE	18/11/24	148.6KB	Share
CUV	Final Director's Interest Notice - Brenda Shanahan		17/10/24	240.12KB	Share
CUV	Results of Meeting		16/10/24	88.49KB	Share
CUV	Managing Director Presentation	PRICE SENSITIVE	16/10/24	1.33MB	Share
CUV	Chair's Address		16/10/24	117.74KB	Share
CUV	Appendix 3Y - Karen Agersborg		03/10/24	272.56KB	Share
CUV	Notification of cessation of securities - CUV		02/10/24	13.5KB	Share
CUV	Canadian New Drug Submission for SCENESSE in EPP filed	PRICE SENSITIVE	01/10/24	78.42KB	Share
CUV	Update - Notification of buy-back - CUV		27/09/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		26/09/24	15.7KB	Share
CUV	SCENESSE data to be presented at global porphyria conference		20/09/24	67.18KB	Share
CUV	Update - Notification of buy-back - CUV		19/09/24	15.7KB	Share
CUV	Notice of Annual General Meeting/Proxy Form		13/09/24	446.2KB	Share
CUV	Change of AGM Time of Meeting		13/09/24	62.86KB	Share
CUV	Initial Director's Interest Notice - Pearl Grimes		10/09/24	233.67KB	Share
CUV	Initial Director's Interest Notice - Guy van Dievoet		10/09/24	230.29KB	Share
CUV	Initial Director's Interest Notice - Matthew Pringle		10/09/24	230.05KB	Share
CUV	Update - Notification of buy-back - CUV		10/09/24	15.7KB	Share
CUV	Chair's letter to Shareholders		09/09/24	103.42KB	Share
CUV	CLINUVEL Board Renewal, Expansion		06/09/24	80.49KB	Share
CUV	Update - Notification of buy-back - CUV		06/09/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		05/09/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		04/09/24	15.7KB	Share
CUV	CLINUVEL Investor Webinar		30/08/24	63.5KB	Share
CUV	Corporate Governance Statement		29/08/24	212.76KB	Share
CUV	Appendix 4G		29/08/24	263.77KB	Share
CUV	Investor Presentation	PRICE SENSITIVE	29/08/24	183.4KB	Share
CUV	CLINUVEL delivers increases in annual revenue, profit	PRICE SENSITIVE	29/08/24	101.68KB	Share
CUV	Dividend/Distribution - CUV		29/08/24	13.5KB	Share
CUV	Appendix 4E and Annual Report to Shareholders 2024	PRICE SENSITIVE	29/08/24	12MB	Share
CUV	Ceasing to be a substantial holder		23/08/24	823.24KB	Share
CUV	Becoming a substantial holder		22/08/24	1009.13KB	Share
CUV	Vitiligo and Operational Update	PRICE SENSITIVE	21/08/24	94.43KB	Share
CUV	Annual Results Webinar		19/08/24	62.39KB	Share
CUV	Ceasing to be a substantial holder		15/08/24	1.47MB	Share
CUV	Becoming a substantial holder		13/08/24	1.58MB	Share
CUV	Ceasing to be a substantial holder		13/08/24	1.48MB	Share
CUV	Becoming a substantial holder		09/08/24	1.91MB	Share
CUV	Change of Company Secretary		06/08/24	63.48KB	Share
CUV	Ceasing to be a substantial holder		01/08/24	1.35MB	Share
CUV	Becoming a substantial holder		30/07/24	1.55MB	Share
CUV	Notification of cessation of securities - CUV		05/07/24	13.51KB	Share
CUV	Afamelanotide Assists DNA Repair Response Following UVR	PRICE SENSITIVE	05/07/24	90.5KB	Share
CUV	CLINUVEL extends Managing Director Employment Agreement	PRICE SENSITIVE	28/06/24	91.02KB	Share
CUV	Change of Company Secretary		28/06/24	57.78KB	Share

CUV Chair's Letter to Shareholders
05/09/25		145.84KB	Share
CUV Date of Annual General Meeting
03/09/25		66KB	Share
CUV CLINUVEL Annual Results - Investor Webinar
29/08/25		64.06KB	Share
CUV Investor Presentation
28/08/25	PRICE SENSITIVE	1.53MB	Share
CUV Corporate Governance Statement
28/08/25		268.03KB	Share
CUV Appendix 4G
28/08/25		295.41KB	Share
CUV Dividend/Distribution - CUV
28/08/25		13.51KB	Share
CUV CLINUVEL delivers ninth consecutive revenues growth & profit
28/08/25	PRICE SENSITIVE	139.49KB	Share
CUV Appendix 4E and Annual Report to Shareholders 2025
28/08/25	PRICE SENSITIVE	18.09MB	Share
CUV CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
22/08/25	PRICE SENSITIVE	100.09KB	Share
CUV CLINUVEL Annual Results - Investor Webinar
21/08/25		71.54KB	Share
CUV Bioshares Biotech Summit presentation
07/08/25		1.85MB	Share
CUV Presentation to BTIG Biotech Conference
30/07/25		1.4MB	Share
CUV Notification of cessation of securities - CUV
02/07/25		12.69KB	Share
CUV German Non-deal Roadshow Presentation
24/06/25		1.74MB	Share
CUV Ceasing to be a substantial holder
19/06/25		960.45KB	Share
CUV Study confirms NB-UVB needed to activate repigmentation
18/06/25	PRICE SENSITIVE	94.13KB	Share
CUV Becoming a substantial holder
18/06/25		873KB	Share
CUV CLINUVEL management update
13/06/25	PRICE SENSITIVE	66.76KB	Share
CUV SCENESSE successfully administered to paediatric EPP patient
13/06/25		67.24KB	Share
CUV SCENESSE in Vitiligo - A Global Update
04/06/25		18.55MB	Share
CUV SCENESSE EPP data featured at EADV Symposium
22/05/25		77.38KB	Share
CUV Ceasing to be a substantial holder
09/05/25		1.15MB	Share
CUV CUV recruits 200 patients in Phase III vitiligo trial CUV105
07/05/25	PRICE SENSITIVE	275.36KB	Share
CUV Notification regarding unquoted securities - CUV
23/04/25		16.96KB	Share
CUV Notification of cessation of securities - CUV
09/04/25		12.69KB	Share
CUV Section 708A Cleansing Statement
07/04/25		92.92KB	Share
CUV Application for quotation of securities - CUV
07/04/25		16.47KB	Share
CUV Application for quotation of securities - CUV
07/04/25		15.56KB	Share
CUV Change in substantial holding
01/04/25		1.46MB	Share
CUV Notification of buy-back - CUV
27/03/25		13.13KB	Share
CUV CLINUVEL renews share buy-back program
27/03/25	PRICE SENSITIVE	71.89KB	Share
CUV Update - Notification of buy-back - CUV
27/03/25		15.25KB	Share
CUV Positive preliminary results for PRENUMBRA Instant in stroke
26/03/25	PRICE SENSITIVE	93.68KB	Share
CUV 2025 American Academy of Dermatology Annual Meeting
24/03/25		5.66MB	Share
CUV CLINUVEL management update
18/03/25	PRICE SENSITIVE	64.26KB	Share
CUV CLINUVEL Unveils Vitiligo Program for AAD 2025
04/03/25		108.92KB	Share
CUV CLINUVEL Investor Webinar
28/02/25		60.69KB	Share
CUV Chair Letter to Shareholders
28/02/25		84.04KB	Share
CUV Half Year Results Presentation
27/02/25	PRICE SENSITIVE	848.02KB	Share
CUV Half Year Results Announcement
27/02/25	PRICE SENSITIVE	130.47KB	Share
CUV Appendix 4D and Half Year Report
27/02/25	PRICE SENSITIVE	885.32KB	Share
CUV CLINUVEL Investor Webinar
20/02/25		109.21KB	Share
CUV Change in substantial holding
17/02/25		1.31MB	Share
CUV Preliminary results from SCENESSE adolescent EPP study
10/02/25	PRICE SENSITIVE	117.52KB	Share
CUV Vitiligo - CUV105 Study Update
20/01/25	PRICE SENSITIVE	2.65MB	Share
CUV SCENESSE Argentinian distribution agreement
17/01/25		68.34KB	Share
CUV Managing Director Letter to Shareholders
23/12/24		96.75KB	Share
CUV Health Canada validates SCENESSE New Drug Submission
23/12/24	PRICE SENSITIVE	68.68KB	Share
CUV Revised Securities Trading Policy
18/12/24		211.55KB	Share
CUV Becoming a substantial holder
06/12/24		1.24MB	Share
CUV Chair's letter to Shareholders
05/12/24	PRICE SENSITIVE	83.86KB	Share
CUV Notification of cessation of securities - CUV
04/12/24		12.69KB	Share
CUV SCENESSE dosage expansion under review by EMA
20/11/24	PRICE SENSITIVE	87.02KB	Share
CUV CLINUVEL Bell Potter Healthcare Conference Presentation
18/11/24		430.71KB	Share
CUV CLINUVEL prioritises three strategic programs
18/11/24	PRICE SENSITIVE	148.6KB	Share
CUV Final Director's Interest Notice - Brenda Shanahan
17/10/24		240.12KB	Share
CUV Results of Meeting
16/10/24		88.49KB	Share
CUV Managing Director Presentation
16/10/24	PRICE SENSITIVE	1.33MB	Share
CUV Chair's Address
16/10/24		117.74KB	Share
CUV Appendix 3Y - Karen Agersborg
03/10/24		272.56KB	Share
CUV Notification of cessation of securities - CUV
02/10/24		13.5KB	Share
CUV Canadian New Drug Submission for SCENESSE in EPP filed
01/10/24	PRICE SENSITIVE	78.42KB	Share
CUV Update - Notification of buy-back - CUV
27/09/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
26/09/24		15.7KB	Share
CUV SCENESSE data to be presented at global porphyria conference
20/09/24		67.18KB	Share
CUV Update - Notification of buy-back - CUV
19/09/24		15.7KB	Share
CUV Notice of Annual General Meeting/Proxy Form
13/09/24		446.2KB	Share
CUV Change of AGM Time of Meeting
13/09/24		62.86KB	Share
CUV Initial Director's Interest Notice - Pearl Grimes
10/09/24		233.67KB	Share
CUV Initial Director's Interest Notice - Guy van Dievoet
10/09/24		230.29KB	Share
CUV Initial Director's Interest Notice - Matthew Pringle
10/09/24		230.05KB	Share
CUV Update - Notification of buy-back - CUV
10/09/24		15.7KB	Share
CUV Chair's letter to Shareholders
09/09/24		103.42KB	Share
CUV CLINUVEL Board Renewal, Expansion
06/09/24		80.49KB	Share
CUV Update - Notification of buy-back - CUV
06/09/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
05/09/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
04/09/24		15.7KB	Share
CUV CLINUVEL Investor Webinar
30/08/24		63.5KB	Share
CUV Corporate Governance Statement
29/08/24		212.76KB	Share
CUV Appendix 4G
29/08/24		263.77KB	Share
CUV Investor Presentation
29/08/24	PRICE SENSITIVE	183.4KB	Share
CUV CLINUVEL delivers increases in annual revenue, profit
29/08/24	PRICE SENSITIVE	101.68KB	Share
CUV Dividend/Distribution - CUV
29/08/24		13.5KB	Share
CUV Appendix 4E and Annual Report to Shareholders 2024
29/08/24	PRICE SENSITIVE	12MB	Share
CUV Ceasing to be a substantial holder
23/08/24		823.24KB	Share
CUV Becoming a substantial holder
22/08/24		1009.13KB	Share
CUV Vitiligo and Operational Update
21/08/24	PRICE SENSITIVE	94.43KB	Share
CUV Annual Results Webinar
19/08/24		62.39KB	Share
CUV Ceasing to be a substantial holder
15/08/24		1.47MB	Share
CUV Becoming a substantial holder
13/08/24		1.58MB	Share
CUV Ceasing to be a substantial holder
13/08/24		1.48MB	Share
CUV Becoming a substantial holder
09/08/24		1.91MB	Share
CUV Change of Company Secretary
06/08/24		63.48KB	Share
CUV Ceasing to be a substantial holder
01/08/24		1.35MB	Share
CUV Becoming a substantial holder
30/07/24		1.55MB	Share
CUV Notification of cessation of securities - CUV
05/07/24		13.51KB	Share
CUV Afamelanotide Assists DNA Repair Response Following UVR
05/07/24	PRICE SENSITIVE	90.5KB	Share
CUV CLINUVEL extends Managing Director Employment Agreement
28/06/24	PRICE SENSITIVE	91.02KB	Share
CUV Change of Company Secretary
28/06/24		57.78KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $10.65		Change -0.010(0.09%)		Mkt cap ! $536.8M

Open	High	Low	Value	Volume
$10.80	$10.80	$10.55	$1.084M	101.5K

Buyers (Bids)

No.	Vol.	Price($)
8	385	$10.64

Sellers (Offers)

Price($)	Vol.	No.
$10.66	463	12

View Market Depth

No.	Vol.	Price($)
4	184	10.650
9	480	10.640
7	984	10.630
3	198	10.620
4	1002	10.610

Price($)	Vol.	No.
10.670	403	13
10.680	353	7
10.690	304	6
10.700	125	4
10.710	59	2

Last trade - 15.40pm 12/09/2025 (20 minute delay)


Last $10.69		Change -0.010 ( 0.02 %)
Open	High	Low	Volume
$10.63	$10.76	$10.60	13599
Last updated 15.59pm 12/09/2025 ?

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories